Stephen Weinrib
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1063543163
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,184 of the $11,374 with a category attached, or 80.7%. It is spread thinly across 42 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,754 and has fallen 92.9% since, to $337 in 2025.
Across 519 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- AstraZeneca$992
- Tandem Diabetes Care, Inc.$880
- Lilly USA, LLC$833
- Novo Nordisk$755
- Dexcom, Inc.$590
- plus $5K from 36 others
What the payments were for
- Speaking & faculty fees$5004%
- Travel & lodging$1,60714%
- Food & beverage$9,18481%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$500
- iLet Bionic Pancreas$375
- TWIIST$192
- Kerendia$125
- Wegovy$121
How this compares
$11,374 in reported general payments places this provider in the 75th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 249 | $422,011 |
| JardianceEmpagliflozin | 162 | $203,091 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 112 | $182,970 |
| MounjaroTirzepatide | 102 | $157,073 |
| Tresiba Flextouch U-200Insulin Degludec | 107 | $139,999 |
| Tresiba Flextouch U-100Insulin Degludec | 195 | $128,522 |
| TrulicityDulaglutide | 87 | $127,749 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 89 | $86,230 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 36 | $83,821 |
| FarxigaDapagliflozin Propanediol | 58 | $65,297 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 44 | $46,554 |
| FiaspInsulin Aspart (Niacinamide) | 31 | $44,094 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $37,446 |
| GenotropinSomatropin | 14 | $28,835 |
| InvokanaCanagliflozin | 19 | $25,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $755 | $479,856324 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $833 | $290,414203 claims |
| Boehringer IngelheimJardiance | $314 | $203,091162 claims |
| AstraZenecaFarxiga | $992 | $65,29758 claims |
| Johnson & JohnsonInvokana | $221 | $25,74719 claims |
| BayerKerendia | $381 | $14,51824 claims |
| AbbVieSynthroid | $362 | $4,36841 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $44 | $4,003326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- Lauren BernsteinAsheville$307K
- Hilary ThomasAsheville$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.